Implementing an online program to change benzodiazepine prescription in Portugal: a cluster randomized trial
DOI:
https://doi.org/10.32385/rpmgf.v38i5.13422Palavras-chave:
Benzodiazepines, Prescription, Digital Behaviour Change Intervention (DBCI), Primary health careResumo
Background: The excessive prescription of benzodiazepines (BZD) has long been considered a worldwide public health issue. Despite the existence of a large body of literature regarding interventions to change BZD prescription patterns, most fail to report significant or long-term effects.
Objective: To study the effect of the implementation of a Digital Behaviour Change Intervention (DBCI) online platform – named ePrimaPrescribe – on the BZD prescription pattern. Secondarily, to determine the effect of the platform implementation on diagnosis registration coded in the same months as BZD prescription and the costs for the NHS with co-payment.
Methods: We followed a cluster-randomised design to allocate 18 primary healthcare units, from a region in Portugal. The study included BZD prescriptions from 250 general practitioners (GP) for a period of 12 months before and after intervention implementation.
Results: BZD was more frequently prescribed to elders and females. The most frequently prescribed BZD was alprazolam. Most prescribed BZD had a medium half-life. In most analyses, we did not find any significant change in the BZD prescription pattern. Regarding secondary outcomes, the depressive disorder was the first, anxiety disorder the second, and dementia the fifth most frequently registered diagnosis associated with BZD prescription. BZD’s co-payment represented an average expenditure of approximately 1,300 € per unit per month.
Conclusion: We could not find any significant difference in the BZD prescription pattern after ePrimaPrescribe implementation. Further work is required to explore the factors influencing resistance to BZD prescription patterns.
Downloads
Referências
Lader M. Benzodiazepines revisited: will we ever learn? Addiction. 2011;106(12):2086-109.
Rang HP. Anxiolytic and hypnotic drugs. In: Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP, editors. Rang and Dale’s pharmacology. 9th ed. Elsevier; 2005. p. 515-24. ISBN 978-0-7020-7448-6
Khong TP, De Vries F, Goldenberg JS, Klungel OH, Robinson NJ, Ibáñez L, et al. Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcif Tissue Int. 2012;91(1):24-31.
Brandt J, Leong C. Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R D. 2017;17(4):493-507.
Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0174730.
Thomas RE. Benzodiazepine use and motor vehicle accidents: systematic review of reported association. Can Fam Physician. 1998;44:799-808.
Carlsten A, Waern M, Holmgren P, Allebeck P. The role of benzodiazepines in elderly suicides. Scand J Public Health. 2003;31(3):224-8.
Neutel CI, Patten SB. Risk of suicide attempts after benzodiazepine and/or antidepressant use. Ann Epidemiol. 1997;7(8):568-74.
Cato V, Holländare F, Nordenskjöld A, Sellin T. Association between benzodiazepines and suicide risk: a matched case-control study. BMC Psychiatry. 2019;19(1):317.
De Gage SB, Bégaud B, Bazin F, Verdoux H, Dartigues JF, Pérès K, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345:e6231.
Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66 Suppl 2:9-13.
Ettcheto M, Olloquequi J, Sánchez-López E, Busquets O, Cano A, Manzine PR, et al. Benzodiazepines and related drugs as a risk factor in Alzheimer’s disease dementia. Front Aging Neurosci. 2020;11:344.
Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996.
INFARMED. Benzodiazepinas e análogos 2016 [Internet]. Lisboa: INFARMED; 2017. Available from: https://www.infarmed.pt/documents/15786/2219894/Utlilização+de+Benzodiazepinas+e+análogos/adb100fa-4a77-4eb7-9e67-99229e13154f
INFARMED. Meio ambulatório: monitorização do consumo de medicamentos, dezembro 2019 [Internet]. Lisboa: INFARMED; 2019. Available from: https://www.infarmed.pt/documents/15786/3082483/dezembro/c07bf8cc-75e3-b28f-ae19-78101e6be1fa?version=1.0
Cormack MA, Sweeney KG, Hughes-Jones H, Foot GA. Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice. Br J Gen Pract. 1994;44(378):5-8.
Gorgels WJ, Voshaar RC, Mol AJ, van de Lisdonk EH, van Balkom AJ, van den Hoogen HJ, et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend. 2005;78(1):49-56.
Bueno MB, de Velasco Artaza ER, Fernández Uria J, Gorroñogoitia Iturbe A. Benzocarta: intervención mínima para la desprescripción de benzodiacepinas en pacientes con insomnio [Benzoletter: minimal intervention for deprescribing benzodiazepines in patients with insomnia]. Gac Sanit. 2020;34(6):539-45. Spanish
Baker R, Farooqi A, Tait C, Walsh S. Randomised controlled trial of reminders to enhance the impact of audit in general practice on management of patients who use benzodiazepines. Qual Health Care. 1997;6(1):14-8.
Kollen BJ, van der Veen WJ, Groenhof F, Donker GA, van der Meer K. Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference? BMC Fam Pract. 2012;13:111.
Gentile G, Lapeyre-Mestre M, Micallef J. Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review. BJGP Open. 2020;4(1):bjgpopen20X101014.
Richards D, Toop L, Graham P. Do clinical practice education groups result in sustained change in GP prescribing? Fam Pract. 2003;20(2):199-206.
Vicens C, Bejarano F, Sempere E, Mateu C, Fiol F, Socias I, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry. 2014;204(6):471-9.
Fernandes M, Neves I, Oliveira J, Santos O, Aguiar P, Atalaia P, et al. Discontinuation of chronic benzodiazepine use in primary care: a nonrandomized intervention. Fam Pract. 2022;39(2):241-8.
Oliveira J, Neves I, Fernandes M, Santos O, Maria V. Prescribing and facilitating withdrawal from benzodiazepines in primary health care. Rev Port Med Geral Fam. 2019;35(4):305-12.
Neves IT, Oliveira JS, Fernandes MC, Santos OR, Maria VA. Physicians’ beliefs and attitudes about benzodiazepines: a cross-sectional study. BMC Fam Pract. 2019;20(1):71.
Vicens C, Socias I, Mateu C, Leiva A, Bejarano F, Sempere E, et al. Comparative efficacy of two primary care interventions to assist withdrawal from long term benzodiazepine use: a protocol for a clustered, randomized clinical trial. BMC Fam Pract. 2011;12:23.
Caldas de Almeida JM, Xavier M, editor. Estudo epidemiológico nacional de saúde mental: 1º relatório [Internet]. Lisboa: NOVA Medical School; 2013. ISBN 9789899857605. Available from: https://www.mgfamiliar.net/wp-content/uploads/Relatorio_Estudo_Saude-Mental_2.pdf
Furtado C, Teixeira I. Utilização de benzodiazepinas em Portugal continental (1999-2003) [Benzodiazepine's utilization in Continental Portugal (1999-2003)]. Acta Med Port. 2006;19(3):239-46. Portuguese
Pisco L. Reforma da atenção primária em Portugal em duplo movimento: unidades assistenciais autónomas de saúde familiar e gestão em agrupamentos de centros de saúde [Primary healthcare reform in Portugal on two fronts: autonomous family healthcare units and management of groupings of Health Centers]. Cienc Saude Colet. 2011;16(6):2841-52. Portuguese
Pinto DJ. Modifying factors for drug prescription behaviour in primary care [dissertation]. Lisboa: NOVA Medical School; 2017. Available from: http://hdl.handle.net/10362/33874
Michie S, Van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.
West R, Michie S. A guide to development and evaluation of digital behaviour change interventions in healthcare. Silverback Publishing; 2016. ISBN 9781912141029
National Institute of Health and Care Excellence. Benzodiazepine and z drug withdrawal [Internet]. NICE; 2013. Available from: http://cks.nice.org.uk/benzodiazepine-and-z-drug-withdrawal
Direção-Geral da Saúde. Tratamento sintomático da ansiedade e insónia com benzodiazepinas e fármacos análogos. Lisboa: DGS; 2011.
Direção-Geral da Saúde. Tratamento sintomático da ansiedade e insónia com benzodiazepinas e fármacos análogos: norma de orientação clínica nº 055/2011, de 27/10/2011, atualizada em 21/01/2015. Lisboa: DGS; 2015.
Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-51.
All Wales Medicines Strategy Group. Educational pack: material to support appropriate prescribing of hypnotics and anxiolytics across Wales [Internet]. Vale of Glamorgan: AWMSG; 2016. Available from: https://www.cambridgeshireandpeterboroughccg.nhs.uk/easysiteweb/getresource.axd?assetid=19617&type=0&servicetype=1
Reis TA. Change in prescribing patterns of benzodiazepines after training of general practitioners [dissertation]. Lisbon: NOVA Medical School; 2015. Available from: http://hdl.handle.net/10362/15714
Agresti A. An introduction to categorical data analysis. 3rd ed. Wiley; 2018. ISBN 9781119405283
R Foundation. R foundation for statistical computing. R: a language and environment for statistical computing [homepage]. R Foundation; 2019. Available from: https://www.r-project.org/
R Studio. RStudio: integrated development for R. Boston: RStudio, Inc.; 2015. Available from: https://www.rstudio.com/products/rstudio/
Wickham H, Chang W, Wickham MH. Package ‘ggplot2’: creat elegant data vis using gramm graph version 2 [Internet]. Available from: https://cran.microsoft.com/snapshot/2015-01-06/web/packages/ggplot2/ggplot2.pdf
Sjöstedt C, Ohlsson H, Li X, Sundquist K. Socio-demographic factors and long-term use of benzodiazepines in patients with depression, anxiety or insomnia. Psychiatry Res. 2017;249:221-5.
De las Cuevas C, Sanz E, De la Fuente JA, Cabrera C, Mateos A. Prescribed daily doses and ‘risk factors’ associated with the use of benzodiazepines in primary care. Pharmacoepidemiol Drug Saf. 1999;8(3):207-16.
Vilaça A, Vieira A, Fernandes A, Ribeiro D, Esteves I. Characterisation of benzodiazepine use in an older population registered in family health units in the Region of Minho, Portugal. Geriatrics. 2019;4(1):27.
Lukačišinová A, Fialová D, Peel NM, Hubbard RE, Brkic J, Onder G, et al. The prevalence and prescribing patterns of benzodiazepines and Z-drugs in older nursing home residents in different European countries and Israel: retrospective results from the EU SHELTER study. BMC Geriatr. 2021;21(1):277.
Grant BF, Weissman MM. Gender and the prevalence of psychiatric disorders. In: Narrow WE, First MB, Sirovatka PJ, Regier DA, editors. Age and gender considerations in psychiatric diagnosis: a research agenda for DSM-V. American Psychiatric Publishing; 2007. p. 31-45.
Anthierens S, Habraken H, Petrovic M, Christiaens T. The lesser evil? Initiating a benzodiazepine prescription in general practice: a qualitative study on GPs’ perspectives. Scand J Prim Health Care. 2007;25(4):214-9.
Maun A, Wessman C, Sundvall PD, Thorn J, Björkelund C. Is the quality of primary healthcare services influenced by the healthcare centre’s type of ownership? An observational study of patient perceived quality, prescription rates and follow-up routines in privately and publicly owned primary care centres. BMC Health Serv Res. 2015;15:417.
Furtado C. Psicofármacos: evolução do consumo em Portugal Continental (2000-2012) [Internet]. Lisboa: INFARMED; 2013. Available from: https://www.infarmed.pt/documents/15786/17838/psicofarmacos_relatorio2013+%281%29.pdf/3e52568f-7f90-47c8-9903-d128395c73e5
Smith AJ, Tett SE. Improving the use of benzodiazepines: is it possible? A non-systematic review of interventions tried in the last 20 years. BMC Health Serv Res. 2010;10:321.
Downloads
Publicado
Edição
Secção
Licença
Direitos de Autor (c) 2022 Revista Portuguesa de Medicina Geral e Familiar
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-NãoComercial-SemDerivações 4.0.
Os autores concedem à RPMGF o direito exclusivo de publicar e distribuir em suporte físico, electrónico, por meio de radiodifusão ou em outros suportes que venham a existir o conteúdo do manuscrito identificado nesta declaração. Concedem ainda à RPMGF o direito a utilizar e explorar o presente manuscrito, nomeadamente para ceder, vender ou licenciar o seu conteúdo. Esta autorização é permanente e vigora a partir do momento em que o manuscrito é submetido, tem a duração máxima permitida pela legislação portuguesa ou internacional aplicável e é de âmbito mundial. Os autores declaram ainda que esta cedência é feita a título gratuito. Caso a RPMGF comunique aos autores que decidiu não publicar o seu manuscrito, a cedência exclusiva de direitos cessa de imediato.
Os autores autorizam a RPMGF (ou uma entidade por esta designada) a actuar em seu nome quando esta considerar que existe violação dos direitos de autor.
